相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
100.0%
暂无批准数据
- Verrica Pharmaceuticals raised approximately $50 million through a private placement financing to retire debt and extend operations into mid-2027. - The company will use $35 million to fully repay OrbiMed debt obligations, eliminating restrictive covenants and interest payments. - Financing enables advancement of VP-315 Phase 3 trials for basal cell carcinoma and global Phase 3 program for common warts starting before end of 2025. - YCANTH remains the only FDA-approved treatment for molluscum contagiosum, affecting approximately 6 million Americans primarily children.
- Virginia lawmakers unanimously approved economic development packages worth over $10 million each for AstraZeneca's multibillion-dollar manufacturing plant in Albemarle County and Eli Lilly's facility in Goochland County. - The AstraZeneca project represents part of a $50 billion five-year investment plan and will be the company's largest global manufacturing investment, strategically located near the University of Virginia's Manning Institute of Biotechnology. - Both pharmaceutical giants are expanding domestic manufacturing capacity amid potential tariff threats, with Eli Lilly committing $50 billion over five years to double its U.S. manufacturing investments. - The Virginia facilities will strengthen a pharmaceutical manufacturing corridor extending from the Shenandoah Valley to Richmond, positioning the state as a major center for advanced pharmaceutical production.
